Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Towards therapeutic choices in ulcerative colitis

Within the past few decades ulcerative colitis has become a worldwide condition, with the highest prevalence reported in developed countries and increasing incidence in developing nations.1 5-aminosalicylic acid has remained the mainstay of treatment in approximately half of patients, although several options are now available for those who become intolerant or refractory to this first-line therapy. Beyond conventional treatments such as corticosteroids and thiopurines, antitumour necrosis factor (TNFα) blockers showed efficacy more than 10 years ago in patients with refractory ulcerative colitis.

email